True innovation that benefits cancer patients
An advanced liquid biopsy platform for early and reliable cancer detection and monitoring
Welcome to GALEAS™
True innovation that benefits patients
Current cancer screening methods can be expensive and invasive, and they don’t always detect relapse early enough.
At Nonacus, we are developing an innovative solution to this problem.
Combining ultra-sensitive genomic techniques with cutting-edge bioinformatics, our GALEAS liquid biopsy platform aims to leverage the unique molecular signature of a tumor to guide treatment decisions, detect cancer early and provide recurrence monitoring to improve patient outcomes.
Ultra-sensitive technologies for detecting clinically actionable variants in primary tumor or liquid biopsy.
Sophisticated tools for designing and analyzing biomarker panels that automate diagnosis and support patient monitoring.
The right treatment, for the right patient, at the right time
Targeted genomic profiling of tumor samples
Determining the molecular signature and identifying the driver mutations of a cancer provides an insight into the tumor classification and possible treatment pathways. Targeted next generation sequencing is a cost-effective approach that detects clinically relevant and actionable biomarkers associated with a cancer, like single nucleotide variants, indels, copy number variants and fusions. It can help identify appropriate therapeutic paths like immunotherapy and provide a genetic signature specific to an individual tumor that can be used in monitoring.
The potential of liquid biopsy
Unlike tissue sampling, which can only really be done once or twice on any individual, liquid biopsy testing offers the possibility of serial sampling of a patient throughout their treatment. This allows the response of a patient to treatment to be measured, and resistance and relapse can be spotted earlier than current screening methods. It also offers the possibility to profile tumors where a tissue biopsy is difficult or undesirable.
“We are striving to develop a suite of meaningful non-invasive tools that can have real impact on the diagnosis and treatment of patients with cancer.”
Chris Sale, CEO Nonacus
Ultra-sensitive primary tumor analysis that can detect clinically relevant SNVs, indels and CNVs in both solid and liquid biopsies
We are developing carefully curated pan-cancer panels that are validated on cell-free DNA and FFPE samples, as well as genomic DNA, giving you the option of profiling either primary, metastatic or liquid biopsies.
Ultra-sensitive MRD panels for longitudinal monitoring
Our ultra-sensitive, personalized MRD panels are designed for detecting tumor or patient specific variants from tumor derived cell-free DNA at multiple time points during treatment, opening up the possibility to track a patient’s response to treatment.
Optimized bioinformatics for clinical environments
Starting with GALEAS Bladder, our GALEAS platform will support the analysis of Nonacus panels, optimizing variant detection from primary tumor screening through to long-term longitudinal monitoring, ultimately delivering an integrated platform for cancer care.